# Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma

> **NCT03088176** · PHASE1 · UNKNOWN · sponsor: **West Cancer Center** · enrollment: 4 (actual)

## Conditions studied

- Melanoma
- BRAF Gene Mutation

## Interventions

- **DRUG:** Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil
- **DRUG:** Talimogene Laherparep 100 Mil Pfu/Ml 1Ml
- **DRUG:** Dabrafenib
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT03088176
- **Lead sponsor:** West Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-06-25
- **Primary completion:** 2020-11-30
- **Final completion:** 2021-06-30
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2020-10-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03088176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03088176, "Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03088176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*